Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Common Equity (2016 - 2025)

Bio-Techne (TECH) has 16 years of Common Equity data on record, last reported at $2.0 billion in Q4 2025.

  • For Q4 2025, Common Equity fell 3.25% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, down 3.25%, while the annual FY2025 figure was $1.9 billion, 7.25% down from the prior year.
  • Common Equity reached $2.0 billion in Q4 2025 per TECH's latest filing, up from $2.0 billion in the prior quarter.
  • Across five years, Common Equity topped out at $2.1 billion in Q3 2024 and bottomed at $1.5 billion in Q1 2021.
  • Average Common Equity over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2023.
  • Peak YoY movement for Common Equity: increased 19.88% in 2021, then fell 8.08% in 2025.
  • A 5-year view of Common Equity shows it stood at $1.7 billion in 2021, then rose by 7.32% to $1.8 billion in 2022, then grew by 7.47% to $2.0 billion in 2023, then grew by 5.85% to $2.1 billion in 2024, then decreased by 3.25% to $2.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $2.0 billion in Q4 2025, $2.0 billion in Q3 2025, and $1.9 billion in Q2 2025.